Vitamin D3 for Life

Live Enlightened

Article

Chronic Kidney Disease and Altered Vitamin D Metabolism: Full Evidence Review

Previous related page25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D: Physiological Meaning and Regulation: Study SummaryNext related pageChronic Kidney Disease and Altered Vitamin D Metabolism: Study Summary
Study at a glance

How can chronic kidney disease change vitamin D processing?

This evidence review explains how chronic kidney disease can disrupt vitamin D processing. Healthy kidneys recover vitamin D compounds from filtered blood and convert an earlier form into calcitriol, the active vitamin D hormone. Kidney disease can disturb recovery, activation, breakdown and hormone control. The problem is more complex than simply having fewer kidney cells.

Why can active vitamin D fall in kidney disease?

Loss of functioning kidney tissue can reduce activation. Hormones also affect the remaining tissue: fibroblast growth factor 23 (FGF23) can reduce activation, while parathyroid hormone usually promotes it. Kidney damage may alter how vitamin D compounds are recovered. However, one small study found that reducing loss of vitamin D-binding protein in urine did not produce matching changes in blood vitamin D. Urinary loss alone therefore does not explain every low result.

Does kidney disease simply speed up vitamin D breakdown?

No. Some evidence shows slower overall vitamin D processing and removal in chronic kidney disease. Reduced production can coexist with reduced breakdown. A routine vitamin D blood result and an active-hormone result answer different questions, and neither alone describes the whole disturbance. Cells outside the kidneys may still activate vitamin D locally, without replacing the kidneys’ supply to the blood.

What did vitamin D treatments show in kidney disease?

Different vitamin D preparations act at different stages. Trials found inconsistent effects of ordinary supplements on parathyroid hormone, while some other preparations lowered it more consistently. A better hormone result does not by itself prove better survival, heart health or long-term bone health. Disease stage and the treatment used matter, so the evidence does not describe one identical response for everyone with kidney disease.

Read the full article below ↓

Chronic kidney disease can alter vitamin D physiology at several points at once. Loss of functioning renal tissue can reduce production of circulating calcitriol, but the disturbance is not simply a matter of having fewer kidney cells available to activate vitamin D. Changes in proximal-tubule handling of 25-hydroxyvitamin D [25(OH)D], endocrine regulation by parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23), and altered vitamin D catabolism can all change the relationship between vitamin D status and active-hormone availability. This wider interaction is central to Vitamin D and Kidneys. For a shorter explanation of the evidence, see Chronic Kidney Disease and Altered Vitamin D Metabolism: Study Summary.

The kidney controls more than the final activation reaction

The familiar description of renal vitamin D metabolism is that 25(OH)D reaches the kidney and is converted by CYP27B1 into 1,25-dihydroxyvitamin D [1,25(OH)₂D, or calcitriol]. That reaction is fundamental, but it sits inside a much larger renal system. Most circulating 25(OH)D is protein-bound, particularly to vitamin D-binding protein (DBP). After filtration at the glomerulus, part of this DBP-bound pool is recovered by proximal tubular cells through receptor-mediated uptake involving megalin and cubilin. The recovered 25(OH)D can then become available for intracellular metabolism.

The proximal tubule therefore links substrate conservation with endocrine activation. If filtered vitamin D metabolites were simply lost into the urine, the kidney would not only lose potential substrate but also weaken the pathway supplying CYP27B1. Experimental evidence has made this recovery mechanism particularly clear in megalin-deficient models, where loss of DBP-bound vitamin D metabolites is accompanied by major disturbance of vitamin D and mineral physiology.

Once 25(OH)D reaches the renal cell, its fate is also governed by competing enzyme pathways. CYP27B1 produces calcitriol, whereas CYP24A1 participates in further metabolism of both 25(OH)D and calcitriol. The wider relationship between these opposing pathways is explained in Vitamin D Enzyme Pathways (CYP27B1 / CYP24A1).

Why declining kidney function can lower calcitriol

As chronic kidney disease progresses, the amount of functioning renal tissue available to perform tightly regulated endocrine metabolism can decline. This provides one direct route to lower calcitriol production. Fewer functioning nephrons and impaired proximal-tubule biology can reduce the kidney’s capacity to recover substrate and carry out CYP27B1-dependent conversion.

That explanation is important but incomplete. Calcitriol can begin to fall before renal function reaches its most advanced stages, which means the decline cannot always be understood simply by counting remaining nephrons. Endocrine feedback changes during CKD can suppress activation in surviving renal tissue as well.

FGF23 is particularly important. Rising phosphate burden and disturbances in mineral metabolism can increase FGF23 signalling. In the kidney, FGF23 suppresses CYP27B1 and tends to favour CYP24A1 expression. The same surviving nephron can therefore be exposed to signals that actively reduce calcitriol availability rather than merely continuing to produce hormone at its previous rate.

PTH acts in the opposite overall direction by stimulating renal CYP27B1. The resulting physiology is not a simple one-hormone switch. CKD can generate rising PTH as calcitriol and calcium-related signalling change, while FGF23 simultaneously restrains calcitriol production. The active-hormone concentration that emerges reflects the balance among these signals and the remaining metabolic capacity of the kidney.

Substrate delivery can also become abnormal

Renal vitamin D activation depends on more than CYP27B1 expression. The enzyme requires access to 25(OH)D substrate. Bosworth and de Boer emphasised that proximal-tubule uptake of filtered DBP-bound 25(OH)D is therefore part of the CKD problem, not merely a transport detail.

Proteinuria provides an obvious reason to suspect altered vitamin D handling because DBP can appear in the urine when renal filtration and tubular recovery are disturbed. However, the evidence prevents a simple causal claim that urinary DBP loss automatically produces low circulating vitamin D status.

In a small clinical study of proteinuric CKD, urinary DBP excretion was dramatically higher than in controls and fell when antiproteinuric treatment reduced proteinuria. Yet plasma DBP, 25(OH)D3 and 1,25(OH)₂D3 did not change correspondingly. The important lesson is that urinary loss can be a marker of disturbed renal handling without being sufficient by itself to explain the circulating vitamin D phenotype.

This is one example of why kidney disease can uncouple individual measurements from the complete physiological process. Filtration, tubular uptake, endocrine activation and systemic concentration are connected, but they are not interchangeable measurements of the same event.

Vitamin D degradation in CKD is not simply accelerated

A second common oversimplification is that low vitamin D activity in CKD must reflect excessive degradation. CYP24A1 does metabolise both 25(OH)D and calcitriol, and FGF23 can shift renal enzyme regulation toward greater catabolic pressure under some conditions. That makes increased degradation biologically plausible in parts of the system.

But CKD evidence does not support turning that plausible mechanism into a universal description. Pharmacokinetic and metabolite evidence reviewed by Bosworth and de Boer indicates that overall vitamin D turnover can actually be reduced in CKD. Formation of the CYP24A1-derived metabolite 24,25-dihydroxyvitamin D can be diminished, and metabolic clearance may slow.

The resulting model is therefore one of impaired metabolism rather than simply excessive disposal. Production of active hormone can be reduced at the same time that parts of the catabolic system are also functioning differently or more slowly. A vitamin D system can be metabolically disturbed in both directions.

This distinction matters because Vitamin D Clearance and Degradation is part of normal regulation, not merely a pathway that removes useful hormone. In healthy physiology, formation and degradation work together to control exposure. CKD can disturb that balance rather than pushing every component toward a single extreme.

PTH, FGF23, calcium and phosphate form a changing endocrine network

The consequences of impaired renal vitamin D metabolism extend directly into mineral homeostasis. Calcitriol normally supports intestinal calcium and phosphate absorption and participates in feedback involving PTH and FGF23. When renal calcitriol production falls, those relationships change.

Reduced calcitriol availability can weaken intestinal calcium absorption and remove part of the normal suppressive influence on PTH. PTH may consequently rise as part of secondary hyperparathyroidism. This is an adaptive response aimed at defending extracellular calcium, but persistent elevation can contribute to abnormal bone and mineral metabolism.

FGF23 often rises early in CKD and promotes phosphate excretion by surviving nephrons while suppressing renal calcitriol production. That response may initially help maintain serum phosphate within a relatively narrow range even as renal excretory capacity declines. Normal serum phosphate at one point in CKD therefore does not prove that phosphate regulation is normal underneath the measurement.

The feedback relationship becomes circular. Disturbed phosphate handling can increase FGF23; higher FGF23 suppresses calcitriol; reduced calcitriol changes calcium absorption and PTH regulation; PTH then acts on kidney and bone in an attempt to preserve mineral balance. The wider calcium component of this system is developed in Vitamin D and Calcium Physiology.

A blood vitamin D result cannot describe the entire renal disturbance

CKD also illustrates why 25(OH)D and calcitriol answer different questions. Serum 25(OH)D describes the main circulating vitamin D status pool, whereas calcitriol is a tightly regulated endocrine output. Kidney disease can disrupt the conversion between those levels without requiring an equivalent change in both measurements.

A person can therefore have a measurable 25(OH)D substrate pool while renal calcitriol production is impaired. Conversely, endocrine compensation can sometimes preserve aspects of mineral homeostasis despite substantial changes in underlying renal vitamin D metabolism. One isolated result cannot show how well substrate recovery, CYP27B1 activation, CYP24A1 metabolism and endocrine feedback are functioning together.

This is a concrete example of the broader principle described in Vitamin D Homeostasis Mechanisms: homeostasis is not maintenance of one static vitamin D number. It is the coordinated adjustment of several interacting processes.

CKD does not eliminate extra-renal vitamin D activation

The kidney is the principal regulated source of circulating calcitriol under ordinary endocrine conditions, but CYP27B1 is also expressed outside the kidney. Immune cells and several other tissues can generate calcitriol locally. This distinction becomes especially important when discussing renal disease.

Loss of renal endocrine production therefore does not mean that every form of vitamin D activation everywhere in the body has stopped. Extra-renal activation is often regulated differently and may support local intracrine or paracrine signalling rather than substantially restoring the circulating endocrine calcitriol pool.

The two statements can therefore both be true: kidney dysfunction can substantially impair systemic calcitriol physiology, and some tissues can retain local CYP27B1-dependent activation. Treating those as contradictory would confuse endocrine and local signalling functions.

Treatment studies show biochemical effects more clearly than patient-level outcomes

Intervention evidence also requires careful interpretation. Trials in CKD have used nutritional vitamin D, calcifediol, calcitriol and vitamin D receptor activators. These interventions do not act at identical points in the pathway, so their effects cannot be treated as interchangeable evidence for “vitamin D treatment.”

A systematic review of randomized trials found inconsistent effects of nutritional vitamin D supplementation on PTH. Calcifediol, calcitriol and paricalcitol more consistently suppressed PTH in the included studies. Active forms and analogues can therefore produce a clearer biochemical endocrine effect than nutritional vitamin D in some CKD settings.

That does not establish complete restoration of normal renal physiology. In studies reporting FGF23, active analogues could increase FGF23, illustrating how changing one arm of the system can provoke another regulatory response. Few trials provided sufficiently comparable bone-metabolism outcomes, and biochemical improvement cannot automatically be converted into proof of better cardiovascular outcomes, survival or long-term skeletal health.

This distinction matters because a reduction in PTH is a specific biochemical outcome. It may be clinically relevant, but it is not a universal proxy for every downstream consequence of CKD-mineral and bone disorder.

The severity and stage of kidney disease change the interpretation

Chronic kidney disease is not one uniform physiological state. Early disease with preserved filtration, proteinuric disease with tubular stress, advanced loss of nephron mass and dialysis-dependent kidney failure can impose different constraints on vitamin D metabolism.

The importance of particular mechanisms can therefore change with disease stage. FGF23 elevation may become relevant while serum phosphate remains apparently controlled. Tubular uptake may be affected by proteinuric injury. Severe loss of functioning renal tissue can increasingly limit endocrine activation capacity. Treatments used in advanced disease can themselves change PTH, FGF23 and metabolite patterns.

For that reason, the phrase “kidney disease lowers vitamin D” compresses several different phenomena. It may refer to low 25(OH)D status, reduced calcitriol production, disturbed substrate handling, altered catabolism, changed endocrine feedback or some combination of them. Those mechanisms need not appear to the same degree in every patient or at every stage.

What the evidence most strongly establishes

The most useful physiological conclusion is that chronic kidney disease disrupts a regulated vitamin D system rather than disabling one isolated reaction. The kidney normally recovers filtered vitamin D substrate, controls production of circulating calcitriol, participates in CYP24A1-mediated metabolism and responds continuously to PTH, FGF23, calcium and phosphate signals.

CKD can disturb each of those relationships. Reduced functional renal mass can constrain endocrine activation. Tubular dysfunction can alter substrate handling. FGF23 can suppress remaining CYP27B1 activity. PTH changes in response to altered mineral and calcitriol physiology. Catabolism and overall metabolite turnover may also change rather than simply accelerate.

The downstream result is a disturbance of endocrine and mineral regulation whose severity cannot be inferred from one vitamin D measurement alone. That is why renal function is not merely another background variable when vitamin D physiology is interpreted. It is part of the machinery that determines what circulating substrate becomes, how long metabolites remain available, and how calcium-phosphate homeostasis responds.

Scientific sources

Cortney Bosworth and Ian H de Boer. Impaired Vitamin D Metabolism in CKD. Seminars in Nephrology. 2013;33(2):158-168. PMID 23465502. PMCID PMC3592201. DOI 10.1016/j.semnephrol.2012.12.016.

Adriana S Dusso. Kidney disease and vitamin D levels: 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and VDR activation. Kidney International Supplements. 2011;1(4):136-141. PMID 25018912. PMCID PMC4089671. DOI 10.1038/kisup.2011.30.

Christina Christodoulou, Maria Tsioufis, and colleagues. Vitamin D Supplementation for Patients with Chronic Kidney Disease: A Systematic Review and Meta-analyses of Trials Investigating the Response to Supplementation and an Overview of Guidelines. Calcified Tissue International. 2021;109:157-178.

Carolina R C Doorenbos, Milton M de Cuba, Liffert Vogt, Ido P Kema, Jacob van den Born, Reinold O B Gans, Gerjan Navis and Martin H de Borst. Antiproteinuric treatment reduces urinary loss of vitamin D-binding protein but does not affect vitamin D status in patients with chronic kidney disease. Journal of Steroid Biochemistry and Molecular Biology. 2012;128(1-2):56-61. PMID 21958677. DOI 10.1016/j.jsbmb.2011.09.002.

Related reading

Original sources

Source

Impaired Vitamin D Metabolism in CKD

Published in Seminars in Nephrology (2013).

Publication details

Cortney Bosworth and Ian H de Boer. Impaired Vitamin D Metabolism in CKD. Seminars in Nephrology. 2013;33(2):158-168. PMID 23465502. PMCID PMC3592201. DOI 10.1016/j.semnephrol.2012.12.016.

Read more →
Source

Vitamin D Supplementation for Patients with Chronic Kidney Disease: A Systematic Review and Meta-analyses of Trials Investigating the Response to Supplementation and an Overview of Guidelines

Published in Calcified Tissue International (2021).

Publication details

Christina Christodoulou, Maria Tsioufis, and colleagues. Vitamin D Supplementation for Patients with Chronic Kidney Disease: A Systematic Review and Meta-analyses of Trials Investigating the Response to Supplementation and an Overview of Guidelines. Calcified Tissue International. 2021;109:157-178.

Read more →
Source

Antiproteinuric treatment reduces urinary loss of vitamin D-binding protein but does not affect vitamin D status in patients with chronic kidney disease

Published in Journal of Steroid Biochemistry and Molecular Biology (2012).

Publication details

Carolina R C Doorenbos, Milton M de Cuba, Liffert Vogt, Ido P Kema, Jacob van den Born, Reinold O B Gans, Gerjan Navis and Martin H de Borst. Antiproteinuric treatment reduces urinary loss of vitamin D-binding protein but does not affect vitamin D status in patients with chronic kidney disease. Journal of Steroid Biochemistry and Molecular Biology. 2012;128(1-2):56-61. PMID 21958677. DOI 10.1016/j.jsbmb.2011.09.002.

Read more →